Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Tratamiento quirúrgico de los tumores neuroendocrinos gastroenteropancreáticos
Información de la revista
Vol. 54. Núm. S1.
Tumores neuroendocrinos gastroenteropancreáticos
Páginas 38-43 (Enero 2007)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 54. Núm. S1.
Tumores neuroendocrinos gastroenteropancreáticos
Páginas 38-43 (Enero 2007)
Tumores neuroendocrinos gastroenteropancreáticos
Acceso a texto completo
Tratamiento quirúrgico de los tumores neuroendocrinos gastroenteropancreáticos
Surgical treatment of gastroenteropancreatic neuroendocrine tumors
Visitas
2903
Andrés Sánchez-Pernaute
Autor para correspondencia
asanchezp.hcsc@salud.madrid.org

Correspondencia: Dr. A. Sánchez-Pernaute. Martín Lago, s/n. 28040 Madrid. España.
, María Elia Pérez Aguirre, Pablo Talavera Eguizábal, Antonio Torres García
Servicio de Cirugía III. Hospital Clínico San Carlos. Madrid. España
Este artículo ha recibido
Información del artículo

La cirugía es el pilar sobre el que descansa el tratamiento de los tumores neuroendocrinos gastroenteropancreáticos. Son tumores que, en general, presentan un buen pronóstico y que muchas veces el único problema al que dan lugar son los síntomas derivados de su secreción endocrina, que se pueden tratar médicamente. Estos hechos han de considerarse siempre que se afronte un tratamiento quirúrgico, que puede ser de agresividad desproporcionada para tan benigna evolución; pero no hay que olvidar que, si existe posibilidad de curación, ésta pasa invariablemente por la exéresis del tumor. No es contraindicación para la resección la presencia de enfermedad a distancia, ya que, por una parte, la cirugía citorreductora tiene un valor indudable y, por otra, existe la posibilidad de resección de las metástasis sin renunciar a la curación, y al menos con la intención de prolongar la supervivencia sin síntomas. El trasplante hepático es controvertido, ya que aunque puede incrementar la supervivencia, la escasez de órganos y la carcinogénesis secundaria a la inmunosupresión cuestionan su utilidad. Recientemente se han diseñado otros tipos de ablación tumoral apoyados por el avance de las técnicas de radiodiagnóstico, que consiguen igualmente buenos resultados para el tratamiento de este tipo peculiar de neoplasias.

Palabras clave:
Tumores neuroendocrinos gastroenteropancreáticos
Tratamiento quirúrgico

Surgery is the cornerstone of the treatment of gastroenteropancreatic tumors. These neoplasms usually have a good prognosis. Endocrine symptoms are often the only problem noticed by the patient and these can be treated pharmacologically. Surgical indication must be considered carefully, as this type of therapy may be too aggressive for benign tumors; on the other hand, the only chance for cure is tumoral resection. Surgery is not contraindicated in cases of distant metastases, as both cytoreductive surgery and metastases resection are associated with an increase in symptom-free survival and, in the latter, to overall survival and sometimes curation. Liver transplantation is controversial; although it can increase survival, its usefulness is limited by the shortage of donors and by carcinogenesis secondary to immunosuppression. Recently, new ablative techniques have been introduced, such as radiofrequency ablation or cryotherapy, both of which achieve good results mainly in the treatment of metastatic disease.

Key words:
Gastroenteropancreatic neuroendocrine tumors
Surgical treatment
El Texto completo está disponible en PDF
Bibliografía
[1.]
R. Arnold.
Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options.
Best Pract Gastroenterol, 19 (2005), pp. 491-505
[2.]
I.M. Modlin, M. Kidd, I. Latich, M.N. Zikusoka, M.D. Shapiro.
Current status of gastrointestinal carcinoids.
Gastroenterology, 128 (2005), pp. 1717-1751
[3.]
E. Solcia, R. Fiocca, F. Sessa.
Morphology and natural history of gastric endocrine tumors.
The stomach as an endocrine organ, pp. 473-498
[4.]
G. Cadiot, P. Laurent-Puig, B. Thuille, T. Lehy, M. Mignon, S. Olschwang.
Is the multiple endocrine neoplasia type 1 gene a suppressor for fundic argyrophil tumors in the Zollinger-Ellison syndrome?.
Gastroenterology, 105 (1993), pp. 579-582
[5.]
J.A. Norton, H.R. Alexander, D.L. Fraker, D.J. Venzon, F. Gibrill, R.T. Jensen.
Possible primary lymph node gastrinoma: occurrence, natural history, and predicrive factors. A prospective study.
[6.]
J.A. Norton, H.R. Alexander, D.L. Fraker, D.J. Venzon, F. Gibrill, R.T. Jensen.
Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome?.
Ann Surg, 239 (2004), pp. 617-626
[7.]
D.K. Bartsch, V. Fendrich, P. Langer, I. Celik, P.H. Kann, M. Rothmund.
Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1.
Ann Surg, 242 (2005), pp. 757-766
[8.]
I.M. Modlin, M. Kidd, I. Latich, M.N. Zikusoka, M.D. Shapiro.
Current status of gastrointestinal carcinoids.
Gastroenterology, 128 (2005), pp. 1717-1751
[9.]
C.G. Moertel, L.H. Weiland, D.M. Nagorney, M.B. Dockerty.
Carcinoid tumor of the appendix: treatment and prognosis.
N Engl J Med, 317 (1987), pp. 1699-1701
[10.]
C.A.G. Proye, J.S. Lokey.
Current concepts in functioning endocrine tumors of the pancreas.
World J Surg, 28 (2004), pp. 1231-1238
[11.]
T.C. Bottger, T. Junginger.
Is preoperative radiographic localization of islet cell tumors in patients with insulinoma necessary?.
Wold J Surg, 17 (1993), pp. 427
[12.]
J. Snajdauf, K. Pycha, M. Rygl, B. Kocmichova, R. Kodet, J. Koutecky, et al.
Papillary cystic and solid tumor of the pancreas-surgical therapy with the CUSA and review of the pediatric literature.
Eur J Pediatr Surg, 9 (1999), pp. 416-419
[13.]
S. Ohwada, T. Ogawa, Y. Tanahashi, S. Nakamura, I. Takeyoshi, T. Ohya, et al.
Fibrin blue sandwich prevents pancreatic fistula following distal pancreatectomy.
World J Surg, 22 (1998), pp. 494-498
[14.]
N.W. Thompson, J. Pasieka, A. Fukuuchi.
Duodenal gastrinomas, duodenotomy and duodenal exploration in the surgical management of Zollinger-Ellison syndrome.
World J Surg, 17 (1993), pp. 455-462
[15.]
H. Dralle, S.L. Krohn, W. Karges, B.O. Boehm, M. Brauckhoff, O. Gimm.
Surgery of respectable non-functioning neuroendocrine pancreatic tumors.
World J Surg, 28 (2004), pp. 1248-1260
[16.]
A. Assalia, M. Gagner.
Laparoscopic pancreatic surgery for islet cell tumors of the pancreas.
World J Surg, 28 (2004), pp. 1239-1247
[17.]
R.S. Chamberlain, D. Canes, K.T. Brown, L. Saltz, W. Jarnagin, Y. Fong, et al.
Hepatic neuroendocrine metastases: does intervention alter outcomes?.
J Am Coll Surg, 190 (2000), pp. 432-445
[18.]
C.G. Moertel.
Karnofsky Memorial Lecture: an odyssey in the land of small tumors.
J Clin Oncol, 5 (1987), pp. 1503-1522
[19.]
I. Norheim, K. Oberg, E. Eheodorsson-Norheim.
Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival.
Ann Surg, 206 (1987), pp. 115-125
[20.]
G.P. McEntee, D.M. Nagorney, L.K. Kvols.
Cytoreductive hepatic surgery for neuroendocrine tumors.
Surgery, 108 (1990), pp. 1091-1096
[21.]
P.J. Allen, W.R. Jarnagin.
Current status of hepatic resection.
Adv Surg, 37 (2003), pp. 29-49
[22.]
J.A. Norton.
Surgical treatment of neuroendocrine metastases.
Best Pract Gastroenterol, 19 (2005), pp. 577-583
[23.]
J.A. Norton, R.T. Jensen.
Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome.
Ann Surg, 240 (2004), pp. 757-773
[24.]
J.M. Sarmiento, G. Heywood, J. Rubin, D.M. Ilstrup, D.M. Nagorney, F.G. Que.
Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.
J Am Coll Surg, 187 (2003), pp. 29-37
[25.]
M. Shouo, M. Gonen, M. D’Angelica, W.R. Jarnagin, R.P. DeMatteo, L.H. Schwartz, et al.
Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection.
J Gastrointest Surg, 7 (2003), pp. 325-330
[26.]
J.N. Vauthey, A. Chaoui, K.A. Do, M.M. Bilimoria, M.J. Fenstermacher, C. Charnsangavej, et al.
Standarized measurement of the future liver remnant prior to extended liver resection: Methodology and clinical associations.
Surgery, 127 (2000), pp. 512-519
[27.]
J.M. Sarmiento, F.G. Que, C.S. Grant, G.B. Thomson, M.B. Farnell, D.M. Nagorney.
Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach.
Surgery, (2002), pp. 976-983
[28.]
J.A. Meléndez, V. Arslan, M.F. Fisher, D. Wuest, W.R. Jarnagin, Y. Fong, et al.
Perioperative outcomes of major hepatic resecions under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction.
J Am Coll Surg, 187 (1998), pp. 620-625
[29.]
U. Plöckinger, B. Wiedenmann.
Management of metastasic endocrine tumors.
Best Pract Gastroenterol, 19 (2005), pp. 553-576
[30.]
F.G. Que, J.M. Sarmiento, D.M. Nagorney.
Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors.
Cancer Control, 9 (2002), pp. 67-79
[31.]
A.C. Gulanikar, G. Kotylak, J. Bitter-Suermann.
Does immunosuppression alter the growth of metastatic liver carcinoid after orthotopic liver transplantation?.
Transplant Proc, 23 (1991), pp. 2197-2198
[32.]
A. Pascher, J. Klupp, P. Neuhaus.
Transplantation in the management of metastatic endocrine tumours.
Best Pract Gastroenterol, 19 (2005), pp. 637-648
[33.]
J. Rosenau, M.J. Bahr, R. Von Wasielewski, M. Mengel, H.H. Schmidt, B. Nashan, et al.
Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors.
Transplantation, 73 (2002), pp. 386-394
[34.]
H. Ahlman, S. Friman, C. Cahlin, O. Nilsson, S. Jansson, B. Wangberg, et al.
Liver transplantation for treatment of metastatic neuroendocrine tumors.
Ann N Y Acad Sci, 1014 (2004), pp. 265-269
[35.]
M. Alessiani, A. Tzakis, S. Todo, A.J. Demetris, J.J. Fung, T.E. Starzl.
Assessment of five-year experience with abdominal organ cluster transplantation.
J Am Coll Surg, 180 (1995), pp. 1-9
[36.]
S. Bengmark, P. Fredlund, L.O. Hafstrom, J. Vang.
Present experiences with hepatic dearterialization in liver neoplasm.
Prog Surg, 13 (1974), pp. 141-166
[37.]
D. O’Toole, P. Ruszniewski.
Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours.
Best Pract Gastroenterol, 19 (2005), pp. 585-594
[38.]
T.D. Atwell, J.W. Charboneau, F.G. Que, J. Rubin, B.D. Lewis, D.M. Nagorney, et al.
Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques.
Cardiovasc Intervent Radiol, 28 (2005), pp. 409-421
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos